Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Digitoxin is a cardiac glycoside derived from the foxglove plant (Digitalis purpurea) and is used for the treatment of heart failure and certain types of cardiac arrhythmias, such as atrial fibrillation. It acts by inhibiting the sodium-potassium ATPase enzyme in cardiac myocytes, leading to increased intracellular calcium concentrations. This results in a positive inotropic effect (increased force of contraction) and negative chronotropic effect (slowed heart rate). Digitoxin has a longer half-life than digoxin and is primarily eliminated via the liver, making it suitable for patients with impaired renal function. However, its use has declined due to limited evidence compared to digoxin and concerns about toxicity[1][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on digitoxin.